# Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

> **NCT00585559** · PHASE3 · TERMINATED · sponsor: **Vanderbilt University Medical Center** · enrollment: 44 (actual)

## Conditions studied

- Aneurysmal Subarachnoid Hemorrhage
- Cerebral Vasospasm

## Interventions

- **DRUG:** Placebos for acetaminophen and N-acetylcysteine
- **DRUG:** APAP 1 gm every 6 hours and N-acetylcysteine placebo
- **DRUG:** NAC IV infusion at 0.5 gm hourly and APAP placebo
- **DRUG:** APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
- **DRUG:** APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly

## Key facts

- **NCT ID:** NCT00585559
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585559, "Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00585559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*